Targeting TNK2/ACK1 Reverses the Immunosuppressive Tumor Microenvironment and Synergizes with Immunochemotherapy in Pancreatic Cancer

Researchers identified TNK2/ACK1 as a key regulator of the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma (PDAC). TNK2/ACK1 is significantly upregulated in PDAC, at least in part via gene amplification and KRAS-G12 mutations.